Belite Bio to Present Phase 3 Stargardt Disease Trial Results at Retina China 2026
Event summary
- Belite Bio will present Phase 3 DRAGON trial results for tinlarebant in Stargardt disease at Retina China 2026 on May 22, 2026.
- Tinlarebant showed a 35.7% reduction in atrophic retinal lesion growth rate vs. placebo.
- The company has initiated a rolling FDA submission for tinlarebant in STGD1 treatment.
- Tinlarebant has received multiple regulatory designations including Breakthrough Therapy and Orphan Drug status.
The big picture
Belite Bio's presentation comes as the retinal disease market seeks first approved treatments for Stargardt disease, a condition affecting thousands of patients worldwide. The company's regulatory designations suggest strong government support for its novel approach to reducing retinal toxins. Success in this niche could position Belite Bio as a key player in the growing ophthalmology therapeutics space.
What we're watching
- Regulatory Pathway
- The pace at which the FDA will review the rolling submission for tinlarebant.
- Commercial Strategy
- How Belite Bio positions tinlarebant in the orphan drug market for Stargardt disease.
- Pipeline Progress
- The timing and results of the DRAGON II and PHOENIX trials for additional indications.